ZNF384 and acute lymphoblastic leukemia: Importantly, the secondary genomic alterations and gene expression profiles for ZNF384-rearranged B-ALL and B/myeloid MPAL cases are essentially indistinguishable, which suggests that ALL-directed therapy should be initiated for patients with newly diagnosed B/myeloid MPAL [79].